NFATC2IP: A Promising Drug Target for Various Diseases (G84901)

Target Name: NFATC2IP

NCBI ID: G84901

NFATC2IP

NFATC2IP: A Promising Drug Target for Various Diseases

NFATC2IP (FLJ14639) is a protein that is expressed in various tissues throughout the body. It is a key regulator of theNotch signaling pathway, which is involved in many cellular processes including stem cell maintenance, tissue regeneration, and inflammation. Despite its importance, little is known about NFATC2IP and its potential role in human disease.

In recent years, researchers have been interested in developing new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One approach that has gained popularity is the use of drug targets, which are proteins that are thought to contribute to the development and progression of these diseases.

NFATC2IP is a potential drug target because it is involved in many important cellular processes that are disrupted in many diseases. For example, NFATC2IP is involved in the regulation of stem cell proliferation and differentiation, which is important for the development of cancer. It is also involved in the regulation of tissue regeneration, which is important for wound healing and repair.

In addition, NFATC2IP is involved in the regulation of inflammation, which is important for many diseases, including cancer and neurodegenerative disorders. It is thought to contribute to the development and progression of these diseases by promoting the recruitment of immune cells to the site of injury or damage.

Given its involvement in so many important cellular processes, it is not surprising that NFATC2IP has been identified as a potential drug target. Researchers are currently working to develop new treatments for a variety of diseases that target NFATC2IP. These treatments may include small molecules, antibodies, and other biochemicals that can interact with the protein to prevent or reverse its effects.

While the development of new treatments for diseases that target NFATC2IP is an exciting area of research, there are also concerns about the potential side effects and risks associated with these treatments. For example, the use of small molecules and antibodies to target NFATC2IP may have unintended consequences, such as affecting the normal functions of other cells in the body.

Overall, while NFATC2IP is a promising drug target, further research is needed to fully understand its potential role in human disease. Researchers are currently working to develop new treatments for a variety of diseases that target NFATC2IP, and these treatments have the potential to improve the health and well-being of many people.

Protein Name: Nuclear Factor Of Activated T Cells 2 Interacting Protein

Functions: In T-helper 2 (Th2) cells, regulates the magnitude of NFAT-driven transcription of a specific subset of cytokine genes, including IL3, IL4, IL5 and IL13, but not IL2. Recruits PRMT1 to the IL4 promoter; this leads to enhancement of histone H4 'Arg-3'-methylation and facilitates subsequent histone acetylation at the IL4 locus, thus promotes robust cytokine expression (By similarity). Down-regulates formation of poly-SUMO chains by UBE2I/UBC9 (By similarity)

The "NFATC2IP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NFATC2IP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets